title: Large-cell neuroendocrine carcinoma of the lung harboring EGFR mutation and responding to gefitinib.
authors: Medical Oncology Unit of Respiratory Tract and Sarcomas, New Drugs Development Division, European Institute of Oncology, Via Ripamonti 435, 20141 Milan, Italy. tommaso.de-pas@ieo.it
authors: Tommaso M
authors: TM
authors: De Pas
authors: Monica
authors: M
authors: Giovannini
authors: Michela
authors: M
authors: Manzotti
authors: Giuseppe
authors: G
authors: Trifirò
authors: Francesca
authors: F
authors: Toffalorio
authors: Chiara
authors: C
authors: Catania
authors: Lorenzo
authors: L
authors: Spaggiari
authors: Roberto
authors: R
authors: Labianca
authors: Massimo
authors: M
authors: Barberis
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001483:Base Sequence; D018287:Carcinoma, Large Cell / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D018278:Carcinoma, Neuroendocrine / Q000188:drug therapy* / Q000235:genetics / Q000473:pathology; D005260:Female; D000077156:Gefitinib; D018773:Genes, erbB-1; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008969:Molecular Sequence Data; D009154:Mutation; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011799:Quinazolines; D000077156:Gefitinib